Novartis India

Which are the latest news on Novartis India?

Why is Novartis India Ltd falling/rising?

As of 14-Jun, Novartis India Ltd's stock price is declining, currently at 1,303.85, down 1.91%. Despite being net-debt free and showing long-term growth, recent performance indicates downward pressure and short-term weakness.

As of 14-Jun, Novartis India Ltd's stock price is falling, currently at 1,303.85, reflecting a decrease of 25.45 points or 1.91%. This decline is evident in today's performance, where the stock underperformed its sector by 2.54%. Additionally, the stock reached an intraday low of Rs 1293.5, marking a drop of 2.69%.<BR><BR>The stock's recent performance over the past week shows a significant decline of 6.12%, contrasting with the Sensex, which has gained 1.73%. Furthermore, there is a notable decrease in investor participation, with delivery volume dropping by 26.68% compared to the 5-day average. Although the stock remains above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, indicating a short-term weakness.<BR><BR>Despite these negative indicators, the company is net-debt free and has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 44.49%. However, the current market conditions and recent performance suggest that the stock is experiencing downward pressure.

How big is Novartis India?

As of 10th June, Novartis India Ltd has a market capitalization of 3,253.00 Cr, categorized as Small Cap, with recent net sales of 354.33 Cr and net profit of 93.18 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Novartis India Ltd has a market capitalization of 3,253.00 Cr, categorized as Small Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 354.33 Cr, while the sum of Net Profit for the same period is 93.18 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is for March 2025, with Shareholder's Funds amounting to 784.96 Cr and Total Assets valued at 932.33 Cr.

Who are in the management team of Novartis India?

The management team of Novartis India includes C Snook (Chairman), Sanjay Murdeshwar (Vice Chairman & Managing Director), Shilpa Joshi (CFO), and several independent directors. They are responsible for guiding the company's strategy and ensuring regulatory compliance.

The management team of Novartis India includes the following key members:<BR><BR>- **C Snook**: Chairman (Non-Executive)<BR>- **Jai Hiremath**: Independent Director<BR>- **Sandra Martryes**: Independent Director<BR>- **Sanjay Murdeshwar**: Vice Chairman & Managing Director<BR>- **Sanker Parameswaran**: Independent Director<BR>- **Nikhil Malpani**: Company Secretary & Compliance Officer<BR>- **Shilpa Joshi**: Whole Time Director & Chief Financial Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Novartis India?

Novartis India's peers include RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs. In terms of performance, Novartis India has a 1-year return of 29.32%, higher than Dishman Carbogen but lower than SMS Pharma's 49.20%.

Peers: The peers of Novartis India are RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience and Novartis India, while Average management risk is found at Gufic BioScience, SMS Pharma, Aarti Drugs, and Morepen Labs, and the rest. Growth is rated as Good at Unichem Labs and Novartis India, while Below Average growth is seen at RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, and Morepen Labs. In terms of Capital Structure, Excellent is noted for RPG LifeScience and Novartis India, Good for Unichem Labs and Aarti Drugs, and Average for Gufic BioScience and SMS Pharma, while Below Average is found at Panacea Biotec, Solara Active, Dishman Carbogen, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMS Pharma at 49.20%, while Dishman Carbogen has the lowest at -38.27%. Novartis India's 1-year return of 29.32% is higher than that of Dishman Carbogen but lower than that of SMS Pharma. Additionally, Dishman Carbogen and Panacea Biotec have negative six-month returns.

What does Novartis India do?

Novartis India Ltd, a subsidiary of Swiss pharmaceutical company Novartis, manufactures and markets drugs in the Pharmaceuticals & Biotechnology industry. As of March 2026, it reported net sales of 91 Cr and a net profit of 25 Cr, with a market cap of INR 3,253 Cr.

Overview:<BR>Novartis India Ltd is engaged in the manufacturing and marketing of drugs and pharmaceutical products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>Incorporated on 13 December 1947, Novartis India Ltd is a subsidiary of the Swiss pharmaceutical giant Novartis. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 91 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 3,253 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.91% <BR>Debt-Equity: -0.81 <BR>Return on Equity: 11.39% <BR>Price to Book: 3.96 <BR><BR>Contact Details:<BR>Address: The Inspire BKC Part 601 & 701, Bandra Kurla Complex Bandra(E) Mumbai Maharashtra : 400051 <BR>Tel: 91-022-50243000 <BR>Email: india.investors@novartis.com <BR>Website: http://www.novartis.in

Are Novartis India Ltd latest results good or bad?

Novartis India Ltd's latest results show a 7.95% revenue growth with net sales at ₹90.55 crores, the highest in two years; however, net profit declined by 13.80% and operating margins fell to their lowest in eight quarters, indicating operational challenges. Overall, while revenue growth is positive, the decline in profitability raises concerns for investors.

The latest results for Novartis India Ltd present a mixed picture. On one hand, the company achieved a notable revenue growth of 7.95% year-on-year, with net sales reaching ₹90.55 crores, marking the highest quarterly sales in two years. This indicates positive momentum in terms of sales performance.<BR><BR>However, the profitability metrics are concerning. The net profit for the quarter was ₹25.25 crores, which represents a significant decline of 13.80% compared to the previous quarter. Additionally, the operating margin has dropped to 22.77%, the lowest in eight quarters, indicating operational challenges. The profit after tax margin also contracted sharply, falling to 27.89% from 34.93% in the previous quarter.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in net profit and operating margins raises red flags about the company's operational efficiency and cost management. This combination suggests that the results are not entirely favorable, as the deterioration in profitability overshadows the revenue growth. Investors should be cautious and monitor how the company addresses these challenges moving forward.

Should I buy, sell or hold Novartis India Ltd?

Is Novartis India overvalued or undervalued?

As of November 4, 2025, Novartis India is fairly valued with a PE ratio of 19.90, making it a more attractive investment compared to peers like Sun Pharma and Divi's Lab, despite its recent underperformance against the Sensex.

As of 4 November 2025, Novartis India's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 19.90, a Price to Book Value of 0.27, and a PEG ratio of 0.91. These ratios suggest that the stock is reasonably priced compared to its earnings growth potential.<BR><BR>In comparison to its peers, Novartis India stands out with a more favorable valuation than Sun Pharma, which has a PE ratio of 35.41, and Divi's Lab, which has a PE ratio of 78.59. Other peers like Dr. Reddy's Labs and Cipla are also attractive but at higher valuations of 17.36 and 22.35, respectively. While Novartis India has underperformed the Sensex over the past year with a return of -19.75% compared to the Sensex's 5.94%, its current valuation metrics suggest it may be a more appealing investment opportunity relative to its peers.

How has been the historical performance of Novartis India?

Novartis India has experienced fluctuating financial performance, with net sales declining from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, while operating profit significantly improved from INR 12.28 crore to INR 133.38 crore during the same period, indicating a recovery in profitability despite declining sales. Total assets and liabilities also decreased, reflecting reduced financial obligations.

Answer:<BR>The historical performance of Novartis India shows fluctuations in key financial metrics over the years, with notable trends in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Novartis India's net sales have seen a decline from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, with a peak of INR 399.87 crore in March 2022. Total operating income followed a similar trend, decreasing from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025. Operating profit (PBDIT) has improved significantly, rising from INR 12.28 crore in March 2019 to INR 133.38 crore in March 2025, indicating a strong recovery in profitability. Profit before tax also increased from INR 85.77 crore in March 2019 to INR 130.42 crore in March 2025, while profit after tax showed a recovery from a loss of INR 3.72 crore in March 2022 to INR 100.90 crore in March 2025. The company's cash flow from operating activities improved from a negative INR 69 crore in March 2021 to INR 74 crore in March 2025, reflecting better operational efficiency. Total assets decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, while total liabilities also decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, indicating a reduction in financial obligations. Overall, Novartis India has shown a recovery in profitability and operational cash flow despite declining sales and total assets.

Is Novartis India technically bullish or bearish?

As of October 24, 2025, Novartis India is in a bearish trend with strong indications of weakness across multiple technical indicators, including the MACD, Bollinger Bands, and moving averages, showing no immediate signs of reversal.

As of 24 October 2025, the technical trend for Novartis India has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages also indicate bearish momentum. The KST is bearish on both weekly and monthly time frames, while the Dow Theory shows no trend on the weekly but is mildly bearish on the monthly. Overall, the indicators suggest a continued bearish trend with no immediate signs of reversal.

Who are the top shareholders of the Novartis India?

The top shareholder of Novartis India is Novartis AG, holding 70.68% of the shares, followed by Atul Limited with 1.52%, and individual investors who own 23.11%. Additionally, foreign institutional investors hold 0.19%, while mutual funds have negligible holdings.

The top shareholders of Novartis India include Novartis AG, which holds the largest stake at 70.68%. Other notable shareholders include Atul Limited, with a holding of 1.52%, and individual investors who collectively own 23.11% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding a small portion of 0.19%, and mutual funds are represented by six schemes, although they hold 0.0%.

When is the next results date for Novartis India?

No Upcoming Board Meetings

Has Novartis India declared dividend?

Yes, Novartis India Ltd has declared a 500% dividend, amounting to ₹25 per share, with an ex-date of July 23, 2024. The dividend yield is 2.5%, and while recent returns have shown some volatility, the company has demonstrated strong long-term growth and returns.

Novartis India Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 25<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 2.5%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Novartis India experienced a price return of -2.95%, with no dividend return, resulting in a total return of -2.95%.<BR><BR>Over the past year, the company had a price return of -0.8% and a dividend return of 2.33%, leading to a total return of 1.53%.<BR><BR>In the 2-year period, the price return was 36.87%, with a dividend return of 4.26%, culminating in a total return of 41.13%.<BR><BR>For the 3-year period, the price return stood at 69.86% and the dividend return at 7.48%, resulting in a total return of 77.34%.<BR><BR>In the last 4 years, Novartis India recorded a price return of 53.94% and a dividend return of 6.34%, yielding a total return of 60.28%.<BR><BR>Lastly, over the 5-year span, the company achieved a price return of 64.44% and a dividend return of 11.55%, which resulted in a total return of 75.99%.<BR><BR>Overall, Novartis India has declared a significant dividend, and while recent returns have shown some volatility, the longer-term performance reflects strong growth and returns, particularly from dividends.